

Runkett 1631
15
PATENT
Attorney Docket No. 896034605001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

5/16/03

In re application of : Elizabeth K. Barber
Serial No. : 09/966,264
Filed : September 28, 2001
For : **GENE EXPRESSION CONTROL DNA
ELEMENT AND ASSOCIATED PROTEIN**
Group Art Unit 1631
Examiner : Mary K. Zeman

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

RECEIVED

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAY 08 2003

TECH CENTER 1600/2900

Sir:

This statement is submitted in compliance with 37 CFR 1.56. A list of publications not previously submitted is set forth on the attached PTO-1449. A copy of each item listed is enclosed.

Any additional fees required for the proper filing of this Information Disclosure Statement should be withdrawn from the Jones, Day, Reavis & Pogue Deposit Account No. 50-1432, Ref. 896034-605001.

Respectfully submitted,

Barbara E. Arndt

Barbara E. Arndt, Ph.D.
Reg. No. 37,768

Jones, Day, Reavis & Pogue
North Point
901 Lakeside Avenue
Cleveland, Ohio 44114
(216) 586-7575

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited today with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below by:

BARBARA E. ARNDT

May 1, 2003

Date

Signature



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/966,264
		Filing Date	9/28/2001
		First Named Inventor	Elizabeth K. Barber
		Art Unit	1631
		Examiner Name	Mary K. Zeman
Attorney Docket Number	896034605001		
Sheet	1	of	1

RECEIVED

MAY 08 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BARBER, E.K., DASGUPTA, J.D., SHLOSSMAN, S.F., TREVILLYAN, J.M., and RUDD, C.E. The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex. Proc. Natl. Acad. Sci. USA., 86: 3277-3281 (1989).	
		BROWN, S.C., and LUCY, J.A. Dystrophin as a Mechanochemical Transducer in Skeletal Muscle. BioEssays, 15: 413-419 (1993).	
		KOENIG, M., BEGGS, A.H., MOYER, M., SCHERPF, S., HEINDRICH, K., BETTECKEN, T., MENG, G., et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet., 45: 498-506 (1989).	
		RAPAPORT, D., FUCHS, O., NUDEL, U., and YAFFE, D. Expression of the Duchenne muscular dystrophy gene products in embryonic stem cells and their differentiated derivatives. J. Biol. Chem., 267: 21289-21292 (1992).	
		SMITH, L.J., CURTIS, J.E., MESSNER, H.A., SENN, J.S., FURTHMAYR, H., and MCCULLOCH, E.A. Lineage infidelity in acute leukemia. Blood, 61: 1138-1145 (1983).	
		TINSLEY, J.M., BLAKE, D., and DAVIES, K.E. Apo-dystrophin-3: a 2.2 kb transcript from the DMD locus encoding the dystrophin glycoprotein binding site. Human Mol. Genet., 2: 521-524 (1993).	
		VORONOVA, A.F., and SEFTON, B.M. Expression of a new tyrosine protein kinase is stimulated by retrovirus promoter insertion. Nature, 319: 682-685 (1986).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.